Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$6.80 -0.7%	$5.23	$2.32 ▼ $10.13	$367.06M	2.41	964,699 shs	682,299 shs
HUMA Humacyte	$2.41 +1.7%	$1.91	$1.15 ▼ $9.79	$373.84M	2	3.86 million shs	1.52 million shs
KMDA Kamada	$7.15 +3.9%	$6.65	$4.74 ▼ $9.16	$411.16M	0.94	93,845 shs	90,056 shs
TCRX TScan Therapeutics	$1.53 -1.3%	$1.45	$1.02 ▼ $8.51	$86.58M	0.98	416,273 shs	432,576 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	0.00%	-5.52%	-0.44%	+119.55%	-8.05%
HUMA Humacyte	0.00%	-8.49%	+5.80%	-21.26%	-66.38%
KMDA Kamada	0.00%	+0.44%	-0.86%	+1.18%	+35.17%
TCRX TScan Therapeutics	0.00%	-13.89%	+25.00%	0.00%	-81.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	0.4191 of 5 stars	1.3	0.0	2.8	2.5	0.0
HUMA Humacyte	2.3386 of 5 stars	3.5	1.0	2.6	2.5	0.6
KMDA Kamada	3.9241 of 5 stars	3.4	3.0	3.1	1.7	3.1
TCRX TScan Therapeutics	3.7647 of 5 stars	3.5	5.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-7.56% Downside
HUMA Humacyte	3.00	Buy	$11.71	386.07% Upside
KMDA Kamada	2.75	Moderate Buy	$14.67	105.13% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	409.80% Upside

Current Analyst Ratings Breakdown

Latest TCRX, HUMA, KMDA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/14/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/14/2025	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
5/13/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	4.59	N/A	N/A	$3.80 per share	1.79
HUMA Humacyte	$517K	723.09	N/A	N/A	$0.13 per share	18.54
KMDA Kamada	$167.24M	2.46	$0.40 per share	17.90	$4.25 per share	1.68
TCRX TScan Therapeutics	$4.42M	19.58	N/A	N/A	$3.15 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	7/30/2025 (Estimated)
HUMA Humacyte	-$110.78M	-$0.69	N/A	N/A	N/A	N/A	-942.81%	-93.82%	8/12/2025 (Estimated)
KMDA Kamada	$8.28M	$0.29	25.54	22.34	0.97	9.92%	6.30%	4.49%	8/13/2025 (Estimated)
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	8/11/2025 (Estimated)

Latest TCRX, HUMA, KMDA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
3/28/2025	Q4 2024	HUMA Humacyte	-$0.23	-$0.16	+$0.07	-$0.16	$0.64 million	$7.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	18.44	18.44
HUMA Humacyte	N/A	1.10	1.10
KMDA Kamada	N/A	4.84	2.73
TCRX TScan Therapeutics	0.13	9.56	9.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
HUMA Humacyte	44.71%
KMDA Kamada	20.38%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.00%
HUMA Humacyte	5.10%
KMDA Kamada	36.10%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
HUMA Humacyte	150	155.12 million	111.76 million	Optionable
KMDA Kamada	360	57.51 million	36.73 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable

TCRX, HUMA, KMDA, and FULC Headlines

Recent News About These Companies

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Buy" from Brokerages

June 14 at 3:44 AM | marketbeat.com

TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen

June 14 at 2:19 AM | americanbankingnews.com

Wall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to Sell

June 14 at 2:16 AM | marketbeat.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update

June 3, 2025 | marketbeat.com

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

What Analysts Are Saying About TScan Therapeutics Stock

May 10, 2025 | nasdaq.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%

April 17, 2025 | aaii.com

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

April 9, 2025 | markets.businessinsider.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%

April 8, 2025 | aaii.com

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

TScan Therapeutics appoints Camiolo as SVP, Market Access

March 27, 2025 | markets.businessinsider.com

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

March 27, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 10.92%

March 18, 2025 | aaii.com

TScan Therapeutics assumed with an Overweight at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones

March 14, 2025 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, HUMA, KMDA, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$6.80 -0.05 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$6.80 +0.00 (+0.07%)

As of 04:04 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Humacyte NASDAQ:HUMA

$2.41 +0.04 (+1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$2.43 +0.02 (+0.83%)

As of 04:29 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Kamada NASDAQ:KMDA

$7.15 +0.27 (+3.92%)

Closing price 04:00 PM Eastern

Extended Trading

$7.14 -0.02 (-0.21%)

As of 04:04 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

TScan Therapeutics NASDAQ:TCRX

$1.53 -0.02 (-1.29%)

Closing price 04:00 PM Eastern

Extended Trading

$1.52 -0.01 (-0.33%)

As of 04:04 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time